BRENTUXIMAB VEDOTIN MAY CUT RADIATION USE IN PEDIATRIC HODGKIN LYMPHOMA

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2021年 / 11卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1318 / 1318
页数：1
相关论文
共 50 条
  • [21] A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma
    Oak, Eunhye
    Bartlett, Nancy L.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 875 - 882
  • [22] The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
    Lai, Catherine
    Kandahari, Adrese Michael
    Ujjani, Chaitra
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 63 - 71
  • [23] Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma
    Flerlage, Jamie E.
    Metzger, Monika L.
    Wu, Jianrong
    Panetta, John C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (06) : 1217 - 1223
  • [24] Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
    Schad, Aimee
    Pakanati, Abhinandan R.
    Woelich, Susan
    Chilkulwar, Abhishek
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [25] USE OF BRENTUXIMAB VEDOTIN TO TREAT HODGKIN LYMPHOMA IN A PRIVATE SECTOR SETTING IN BRAZIL
    Andrade, F.
    Barreto, T.
    Zagadailov, E.
    Gautam, A.
    Clark, O. A.
    Saad, F.
    Seal, B.
    Dalal, M.
    Baiocchi, O.
    VALUE IN HEALTH, 2017, 20 (09) : A878 - A878
  • [26] PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF WEEKLY DOSING OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA
    Flerlage, J.
    Metzger, M.
    Panetta, J. C.
    HAEMATOLOGICA, 2016, 101 : 36 - 37
  • [27] Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma
    Jamie E. Flerlage
    Monika L. Metzger
    Jianrong Wu
    John C. Panetta
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 1217 - 1223
  • [28] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
    Chen, Runzhe
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
  • [29] Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Rosenzweig, Jaclyn
    Mauguen, Audrey
    Buhtoiarov, Ilia
    Cuglievan, Branko
    Dave, Hema
    Deyell, Rebecca J.
    Flerlage, Jamie E.
    Franklin, Anna K.
    Krajewski, Jennifer
    Leger, Kasey J.
    Marks, Lianna J.
    Norris, Robin E.
    Pacheco, Martha
    Willen, Faye
    Yan, Adam Paul
    Harker-Murray, Paul D.
    Giulino-Roth, Lisa
    BLOOD ADVANCES, 2023, 7 (13) : 3225 - 3231
  • [30] Significance of Brentuximab Vedotin in the Treatment of Hodgkin's Lymphoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (04) : 230 - 231
12345